Doping researcher receives four-year ban for doping

Don’t miss out on the latest CyclingTips updates.

Jump To Comments

USADA has announced a four-year ban for 36-year-old American John Gleaves for an anti-doping rule violation. In addition to being a masters racer, Gleaves also happens to be an expert on the history and ethics of doping.

An associate professor of kinesiology at Cal State Fullerton, Gleaves’s “primary research interest” is listed on his university bio as “doping in sport, which he examines from a variety of sociocultural perspectives.”

He has published articles and books on history and ethics of doping in sport, and in 2015 he was hired by Lance Armstrong’s legal team as an expert witness in the federal government’s fraud case against Armstrong, testifying on the widespread use of performance enhancers in cycling.

According to his bio, Gleaves has served on an anti-doping advisory board for USA Cycling and a working group on the prevalence of doping for the World Anti-doping Agency. He is also the associate editor of the Journal of Olympic Studies and co-director of the International Network for Doping Research.

USADA’s statement noted that Gleaves tested positive for multiple banned substances at US track nationals in August of last year. Specifically, his urine sample registered findings for select oxandrolone metabolites as well as “clomiphene and its metabolite 4-hydroxyclomiphene.”

Gleaves accepted his four-year suspension period, which began on August 31, 2019, the date of his positive sample.

Contacted for comment, a USA Cycling representative said that the organization was aware of the sanction and addressed his membership on a USAC committee.

“John was an original member of USA Cycling’s Anti-Doping Committee, launched in 2016,” USA Cycling said. “The Committee has been inactive since the beginning of 2019, largely due to former Committee member, Kelsey Erickson’s, start at USA Cycling where she oversees the SafeSport and RaceClean programs.”

CyclingTips has reached out to Gleaves for comment.

Editors' Picks